Ocrevus, ocrelizumab
Named-patient access overview. Ocrevus is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Ocrevus
Ocrevus (ocrelizumab) is manufactured by Genentech / Roche and indicated for Relapsing MS and primary progressive MS. It is an anti-CD20 monoclonal antibody (IV infusion) approved by the US FDA in 2017 and may be accessible to international patients through Named Patient Program or personal-import pathways.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Ocrevus
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Ocrevus for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Ocrevus is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Country coverage
Reserve Meds publishes detailed country deep-dives for our most-requested medications. Ocrevus country deep-dives are not yet published; we are expanding coverage as the cohort grows. If you are pursuing Ocrevus for a patient in the UAE, Saudi Arabia, India, Egypt, Pakistan, or another market we serve, submit a request and our clinical team will match the destination to the appropriate regulatory pathway and timeline.
Reserved for you. Ocrevus is in coordination scope for the first cohort. Country-specific pricing and timing are confirmed once a coordinator reviews your case.
Start a request for Ocrevus
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.
Frequently asked questions
How can I get Ocrevus if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Ocrevus for patients through a physician-led, named-patient cross-border pathway. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Ocrevus through named-patient or compassionate-use import?
Yes. Named-patient access (also called compassionate use or personal import) is the core route Reserve Meds operates for Ocrevus. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Ocrevus through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Ocrevus to a patient?
Reserve Meds sources Ocrevus from a DSCSA-compliant US specialty supplier with full traceability and coordinates delivery to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Ocrevus cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Ocrevus?
Submit a 60-second intake through the Reserve Meds patient portal, or message the concierge team on WhatsApp. A named coordinator follows up within 24 hours.